DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Evaluation of two inoculation routes of an adenovirus-mediated viral protein inhibitor in a Crimean-Congo hemorrhagic fever mouse model

Journal Article · · Virus Research
ORCiD logo [1];  [1];  [1];  [1];  [1];  [2];  [3];  [1];  [1];  [1]
  1. Centers for Disease Control and Prevention (CDC), Atlanta, GA (United States)
  2. Centers for Disease Control and Prevention (CDC), Atlanta, GA (United States); US Dept. of Agriculture (USDA), Manhattan, KS (United States). Agricultural Research Service (ARS)
  3. Univ. of California, Riverside, CA (United States)

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne nairovirus with a wide geographic spread that can cause severe and lethal disease. No specific medical countermeasures are approved to combat this illness. The CCHFV L protein contains an ovarian tumor (OTU) domain with a cysteine protease thought to modulate cellular immune responses by removing ubiquitin and ISG15 post-translational modifications from host and viral proteins. Viral deubiquitinases like CCHFV OTU are attractive drug targets, as blocking their activity may enhance cellular immune responses to infection, and potentially inhibit viral replication itself. We previously demonstrated that the engineered ubiquitin variant CC4 is a potent inhibitor of CCHFV replication in vitro. A major challenge of the therapeutic use of small protein inhibitors such as CC4 is their requirement for intracellular delivery, e.g., by viral vectors. In this study, we examined the feasibility of in vivo CC4 delivery by a replication-deficient recombinant adenovirus (Ad-CC4) in a lethal CCHFV mouse model. Since the liver is a primary target of CCHFV infection, we aimed to optimize delivery to this organ by comparing intravenous (tail vein) and intraperitoneal injection of Ad-CC4. While tail vein injection is a traditional route for adenovirus delivery, in our hands intraperitoneal injection resulted in higher and more widespread levels of adenovirus genome in tissues, including, as intended, the liver. However, despite promising in vitro results, neither route of in vivo CC4 treatment resulted in protection from a lethal CCHFV infection.

Research Organization:
Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
SC0014664
OSTI ID:
2471343
Journal Information:
Virus Research, Journal Name: Virus Research Vol. 345; ISSN 0168-1702
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
English

References (23)

Enhanced Delivery of Synthetic Labelled Ubiquitin into Live Cells by Using Next‐Generation Ub–TAT Conjugates journal November 2018
Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis journal October 1993
Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter journal April 1993
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial journal February 2017
Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus journal November 2017
Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease journal September 2017
Ovarian Tumor Domain-Containing Viral Proteases Evade Ubiquitin- and ISG15-Dependent Innate Immune Responses journal December 2007
Immunology of Adenoviral Vectors in Cancer Therapy journal December 2019
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity journal January 2002
Viral vector platforms within the gene therapy landscape journal February 2021
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge journal August 2020
Optimal reference genes for RNA tissue analysis in small animal models of hemorrhagic fever viruses journal November 2023
Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers journal September 1999
A simplified system for generating recombinant adenoviruses journal March 1998
Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection journal January 2020
Lethal Crimean-Congo Hemorrhagic Fever Virus Infection in Interferon α/β Receptor Knockout Mice Is Associated With High Viral Loads, Proinflammatory Responses, and Coagulopathy journal February 2013
Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Processing by the Endoprotease SKI-1/S1P Is Critical for Virus Infectivity journal September 2007
Arterivirus and Nairovirus Ovarian Tumor Domain-Containing Deubiquitinases Target Activated RIG-I To Control Innate Immune Signaling journal November 2011
Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection journal July 2019
Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants journal May 2017
Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application journal May 2020
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines journal October 2020
Adenovirus Vectors: Excellent Tools for Vaccine Development journal January 2021